RXi Gains Exclusive License to Oral Delivery of RNAi Therapeutics Technology from University of Massachusetts
News Feb 11, 2009
RXi Pharmaceuticals Corporation has announced that it has licensed exclusive worldwide rights from the University of Massachusetts Medical School (UMMS) to certain technology for the oral delivery of RNAi therapeutics.
The technology was developed by Dr. Michael Czech, Professor and Chair, Program in Molecular Medicine at UMMS and an RXi founder, and Dr. Gary R. Ostroff, Professor of Molecular Medicine at UMMS and an RXi collaborator. Financial terms were not disclosed.
Going forward, management noted, RXi intends to work with pharmaceutical and biotechnology partners to advance the discovery and development of orally delivered rxRNA™ therapeutics for a host of inflammatory diseases.
The American Society of Human Genetics (ASHG), along with several co-signing organizations, issued a position statement today outlining whether, and to what extent, there is a responsibility to recontact genetic and genomic research participants when new findings emerge that suggest their genetic information should be interpreted differently, which would allow participants to benefit from current genomics advances.READ MORE